163 related articles for article (PubMed ID: 17502458)
1. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.
Cohen JM; Sebire NJ; Harvey J; Gaspar HB; Cathy C; Jones A; Rao K; Cubitt D; Amrolia PJ; Davies EG; Veys P
Blood; 2007 Sep; 110(6):2209-14. PubMed ID: 17502458
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
[TBL] [Abstract][Full Text] [Related]
3. Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring.
Wakabayashi S; Ohashi K; Hanajiri R; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Intern Med; 2010; 49(10):931-5. PubMed ID: 20467179
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
5. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
7. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.
Shaffer DR; Rooney CM; Gottschalk S
Immunotherapy; 2010 Sep; 2(5):663-71. PubMed ID: 20874650
[TBL] [Abstract][Full Text] [Related]
9. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
Savani BN; Pohlmann PR; Jagasia M; Chinratanalab W; Kassim A; Engelhardt B; Greer J; Schuening F; Goodman S
Blood; 2009 Jun; 113(24):6263-4. PubMed ID: 19520823
[No Abstract] [Full Text] [Related]
10. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.
Cohen J; Gandhi M; Naik P; Cubitt D; Rao K; Thaker U; Davies EG; Gaspar HB; Amrolia PJ; Veys P
Br J Haematol; 2005 Apr; 129(2):229-39. PubMed ID: 15813851
[TBL] [Abstract][Full Text] [Related]
11. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; Thijsen SF; Meijer E; Osterhaus AD; Wolthers KC; Boucher CA; Gratama JW; Budel LM; van der Holt B; van Loon AM; Löwenberg B; Verdonck LF; Cornelissen JJ
Br J Haematol; 2001 Jun; 113(3):814-21. PubMed ID: 11380475
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
13. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.
Liu Q; Xuan L; Liu H; Huang F; Zhou H; Fan Z; Zhao K; Wu M; Xu L; Zhai X; Zhang F; Liu C; Sun J; Huang X
Am J Hematol; 2013 Jul; 88(7):550-5. PubMed ID: 23564232
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders.
Shamriz O; Vilk SR; Wolf DG; Ta-Shma A; Averbuch D; Weintraub M; Stepensky P
Clin Immunol; 2014 Apr; 151(2):79-83. PubMed ID: 24584040
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
16. Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease.
Ohga S; Kubo E; Nomura A; Takada H; Suga N; Ishii E; Suminoe A; Inamitsu T; Matsuzaki A; Kasuga N; Hara T
Int J Hematol; 2001 Apr; 73(3):323-6. PubMed ID: 11345197
[TBL] [Abstract][Full Text] [Related]
17. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
Reddy N; Rezvani K; Barrett AJ; Savani BN
Biol Blood Marrow Transplant; 2011 May; 17(5):591-7. PubMed ID: 20732435
[TBL] [Abstract][Full Text] [Related]
18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
19. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
[TBL] [Abstract][Full Text] [Related]
20. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
